CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Accumulated Expenses across 12 years of filings, most recently posting $13.1 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $13.1 million, up 2744.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 2744.47% YoY), and the FY2025 annual result was $13.1 million, up 25.88% from the prior year.
• Other Accumulated Expenses came in at $13.1 million for Q1 2026 at CRISPR Therapeutics AG, roughly flat from $13.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $13.1 million in Q4 2025 to a low of $20000.0 in Q4 2022.
• The 5-year median for Other Accumulated Expenses is $563000.0 (2025), against an average of $3.4 million.
• Across the five-year window, Other Accumulated Expenses tumbled 98.42% in 2022 and soared 25605.0% in 2023, its largest moves.
• CRISPR Therapeutics AG's Other Accumulated Expenses stood at $20000.0 in 2022, then jumped by 25605.0% to $5.1 million in 2023, then surged by 102.63% to $10.4 million in 2024, then gained by 25.88% to $13.1 million in 2025, then changed by 0.0% to $13.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $13.1 million (Q1 2026), $13.1 million (Q4 2025), and $563000.0 (Q3 2025), per Business Quant data.